INTRANASAL TOPIRAMATE POLYMERIC NANOPARTICLES FOR EPILEPSY: IN VITRO AND EX-VIVO INVESTIGATION

  • PRAVIN KUKUDKAR Department of Pharmaceutics, Shrimati Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur (M. S.), India 441002
  • SONIYA RAHATE Department of Pharmaceutics, Shrimati Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur (M. S.), India 441002
  • RASHMI TRIVEDI Department of Pharmaceutics, Shrimati Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur (M. S.), India 441002
  • MILIND UMEKAR Department of Pharmaceutics, Shrimati Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur (M. S.), India 441002
  • JAYSHREE TAKSANDE Department of Pharmaceutics, Shrimati Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur (M. S.), India 441002

Abstract

Objective: The presence of tight junctions in blood-brain barrier creates a major problem for the delivery of drugs and severely affects adequate therapeutic concentration to reach the brain. For the treatment of epilepsy, oral route of administration is most convenient but shows delayed absorption. Moreover, in emergency cases, parenteral administration is not possible as it requires medical assistance. Thus, an alternative route of drug delivery is highly desirable for an effective outcome.


Methods: In the present study, bioadhesive chitosan nanoparticles of topiramate for intranasal administration were prepared by ionotropic gelation method using chitosan as bioadhesive polymer and sodium tripolyphosphate as the crosslinking agent. The prepared nanoparticles were evaluated for physicochemical properties like particle size, surface morphology, drug content, entrapment efficiency, thermal behavior and crystallinity, in vitro drug diffusion, ex vivo bio adhesion, and ex vivo biocompatibility studies in excised sheep nasal mucosa.


Results: Differential scanning calorimetry and x-ray diffraction study showed molecular dispersion of drug into the polymer matrices and conversion of it into an amorphous form. Nanoparticles obtained were discrete in nature (size 313.5 nm) and appropriate for intranasal administration. The topiramate nanoparticles revealed high encapsulation efficacy, strong bioadhesion potential and high ex vivo permeation and did not exhibit any deformity to the nasal mucosa. In vitro drug diffusion of optimized formulation showed 92.91% release of drugs after 180 min. Ex-vivo permeation of drugs across nasal mucosa was 89.03 % after 180 min.


Conclusion: Hence, the intranasal administration of topiramate using chitosan can be a promising alternative for brain targeting and the treatment of epilepsy.

Keywords: Topiramate, Nanoparticles, Intranasal administration, Mucoadhesion, Epilepsy

References

1. Gautam S, Nikalaje Y, Bhadre D, Trivedi R, Umekar M, Taksande J. Development and evaluation of lamotrigine soya lecithin solid dispersion: in vitro and pharmacodynamic investigation. Int J Appl Pharm 2019;12:115-22.
2. Musumeci T, Bonaccorso A, Puglisi G. Epilepsy disease and nose-to-brain delivery of polymeric nanoparticles: an overview. Pharmaceutics 2019;11:118.
3. Fisher RS, Ho J. Potential new methods for antiepileptic drug delivery. CNS Drugs 2002;16:579-93.
4. Bhuva F, Patel LD, Patel K. Factorial design methodology for development of pediatric nasal spray: study on xylometazoline nasal solution used for treatment of nasal congestion. Indian J Pharm Edu Res 2018;52:218-29.
5. Mantry S, Balaji A. Formulation design and characterization of ropinirole hydrochoride microsphere for intranasal delivery. Asian J Pharm Clin Res 2017;10:195-203.
6. López T, Cuevas JL, Jardon G, Gomez E, Ramirez P. Preparation and characterization of antiepileptic drugs encapsulated in sol-gel titania nanoparticles as controlled release system. Med Chem 2015;2:3.
7. Tas C, Ozkan CK, Savaser A, Ozkan Y, Tasdemir U, Altunay H. Nasal administration of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation. Drug Delivery 2009;16:167-75.
8. Dhanda DS, Frey WH, Leopold D, Kompella UB. Approaches for drug deposition in the human olfactory epithelium. Drug Delivery Technol 2005;5:64-72.
9. Gavini E, Rassu G, Sanna V, Cossu M, Giunchedi P. Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: in?vitro/ex?vivo studies. J Pharm Pharmacol 2005;57:287-94.
10. Al-Nemrawi NK, Alsharif SS, Dave RH. Preparation of chitosan-TPP nanoparticles: the influence of chitosan polymeric properties and formulation variables. Int J Appl Pharm 2018;10:60-5.
11. Hagesaether E. Permeation modulating properties of natural polymers–effect of molecular weight and mucus. Int J Pharm 2011;409:150-5.
12. Soni M, Majumdar A, Malviya N. Mucoadhesive chitosan microspheres of gefitinib. Int J Curr Pharm Res 2018;10:9-19.
13. Santos Magalhaes NS, Pontes A, Pereira VM, Caetano MN. Colloidal carriers for benzathine penicillin G: nanoemulsions and nanocapsules. Int J Pharm 2000;208:71-80.
14. Kulkarni A, Bambole VA, Mahanwar PA. Electrospinning of polymers, their modeling and applications. Polymer Plastics Tech Eng 2010;49:427-41.
15. Taksande JB, Sonwane PP, Trivedi RV, Wadher KJ, Umekar MJ. Formulation and pharmacodynamic investigations of lamotrigine microspheres in pentylenetetrazole-induced seizures in mice. Asian J Pharm 2017;11:S216-24.
16. Taksande JB, Umekar MJ. Preparation of intranasal pregabalin microspheres: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Pharm Res 2018;12:112-21.
17. El-din EY, Omar AR. Effect of prenatal administration of therapeutic dose of topiramate on placentae albino rats’ fetuses. Int J Pharm Pharm Sci 2017;9:54-9.
18. Sommer BR, Mitchell EL, Wroolie TE. Topiramate: effects on cognition in patients with epilepsy, migraine headache and obesity. Ther Adv Neurol Disord 2013;6:211-27.
19. Doose DR, Walker SA, Gisclon LG, Nayak RK. Single?dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996;36:884-91.
20. Britzi M, Soback S, Isoherranen N, Rene'H L, Perucca E, Doose DR, et al. Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. Ther Drug Monit 2003;25:314-22.
21. Raj BS, Punitha IS, Bodiwala J. Formulation and evaluation of chitosan prazosin beads by ionotropic gelation method. Int J Res Pharm Chem 2012;2:974-83.
22. Belgamwar VS, Patel HS, Joshi AS, Agrawal A, Surana SJ, Tekade AR. Design and development of nasal mucoadhesive microspheres containing tramadol HCl for CNS targeting. Drug Delivery 2011;18:353-60.
23. Pardeshi CV, Rajput PV, Belgamwar VS, Tekade AR. Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for valsartan. J Microencap 2012;29:103-14.
24. Taksande JB, Wadher KJ, Trivedi RV, Umekar MJ. Development and evaluation of lamotrigine loaded n-trimethyl chitosan microspheres for intranasal administration. Int J Chem Tech Res 2017;10:1-13.
25. Chalikwar SS, Mene BS, Pardeshi CV, Belgamwar VS, Surana SJ. Self-assembled, chitosan grafted PLGA nanoparticles for intranasal delivery: design, development and ex vivo characterization. Polymer Plastics Technol Eng 2013;52:368-80.
26. Pardeshi CV, Belgamwar VS. Controlled synthesis of N, N, N-trimethyl chitosan for modulated bio adhesion and nasal membrane permeability. Int J Bio Macromol 2016;82:933-44.
27. Ma L, Liu C. Preparation of chitosan microspheres by ionotropic gelation under a high voltage electrostatic field for protein delivery. Colloids Surf B 2010;75:448-53.
28. Tiyaboonchai W. Chitosan nanoparticles: a promising system for drug delivery. Naresuan University J 2013;11:51-66.
Statistics
41 Views | 32 Downloads
Citatons
How to Cite
KUKUDKAR, P., RAHATE, S., TRIVEDI, R., UMEKAR, M., & TAKSANDE, J. (2020). INTRANASAL TOPIRAMATE POLYMERIC NANOPARTICLES FOR EPILEPSY: IN VITRO AND EX-VIVO INVESTIGATION. International Journal of Applied Pharmaceutics, 12(5), 258-264. https://doi.org/10.22159/ijap.2020v12i5.37385
Section
Original Article(s)

Most read articles by the same author(s)